GF or GSK HIV Take Over? Speculation

Folks, Greetings. 100% my Speculation.

Lalezari has been in conversation with who I'm presuming to be the GF or GSK. Where in a meeting might have resulted in...

GSK or the GF taking over the HIV indication by somehow incorporating/combining Livimmune with ViiV.

GSK or GF in conjunction with the joint collaboration between ViiV and LIVIMMUNE assumes and incorporates the advancement and development of leronlimab, long-acting leronlimab, leronlimab-PLS, LATCH, leronlimab-Triple Therapy and leronlimab-AAV into their armamentarium to treat HIV only.

This solution could potentially derail the direct threat of G away from CytoDyn and redirect G's threat toward GSK or towards the GF or even towards the private ViiV, resulting in a more indirect suppressive affect towards CytoDyn.

The development and advancement of leronlimab in HIV would be taken over by the GF or by GSK via the private ViiV in partnership with LIVIMMUNE, but the GF or GSK collaborating with ViiV would own the 260 million shares and as leronlimab is developed and advanced through ViiV's workings, CytoDyn's share price would rise. Theoretically, G would no longer attack CytoDyn because, now, it would have no incentive as the HIV indication would then be developed by the GF or by GSK via ViiV. All the work towards HIV would be done by the subsidiary provided by the GF or by GSK to ViiV in partnership with LIVIMMUNE, and not by CytoDyn's dollar.

Either the GF or GSK in collaboration together with ViiV in partnership with LIVIMMMUNE could have conceived the plan which had to be discussed with Lalezari/Blok/Cohen. Much of it would be described in accordance with how ViiV already does things, the way Max Lataillade already understands. A great advantage to CytoDyn is that the development of leronlimab in HIV would then be taken over by either the GF or by GSK in collaboration together with ViiV partnered with LIVIMMUNE and that a major enemy of CytoDyn, G, would then be hindered.

Just throwing this out there.